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Abstract
Cross-communication between different signalling systems is critical for the integration of
multiple and changing environmental influences on individual cells. The epidermal growth
factor receptor (EGFR) has been identified as a key element in the complex signalling network
that is utilized by various classes of cell-surface receptors. This nonclassical mode of
signalling system cross-talk, in distinction to receptor activation induced by cognate ligands,
has been termed ‘signal transactivation’. With the EGFR as the convergence point and
distribution focus, this scenario may involve signals emitted by other members of the tyrosine
kinase family, cytokine receptors, ion channels, G-protein-coupled receptors and integrins.
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EGFR = epidermal growth factor receptor; GPCR = G-protein-coupled receptor; HB-EGF = heparin-binding epidermal growth factor-like growth
factor; LPA = lysophosphatidic acid; MAPK = mitogen-activated protein kinase; PI-3K = phosphatidyl inositol-3 kinase; PDGF = platelet-derived
growth factor; PKC = protein kinase C; RTK = receptor tyrosine kinase.
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Introduction
In complex organisms individual cells communicate
through a variety of molecular messengers and actions,
such as growth factors, hormones, cytokines, neuropep-
tides or cell–cell contact, which are recognized by diverse
signal-generating cell-surface receptors and thereby regu-
late cellular growth, differentiation and survival. One
important membrane-spanning protein that integrates the
information flux from multiple sources is the EGFR, which
was the first mammalian signalling protein to be fully char-
acterized [1]. The EGFR belongs to a family of four closely
related receptor tyrosine kinases (RTKs): EGFR/ErbB1,
HER2/ErbB2/neu, HER3/ErbB3 and HER4/ErbB4. These
RTKs are able to form homodimers or heterodimers, and
regulate a large diversity of biological processes [2,3].
Deregulation of this tightly controlled signalling network by
receptor overexpression, autocrine ligand stimulation or
activating mutations has been frequently implicated in
several types of human cancers, especially of the breast,
ovary, lung and prostate [4,5].
Generally, ligands for the EGFR such as EGF, transforming
growth factor-a or heparin-binding EGF-like growth factor
(HB-EGF) are synthesized as transmembrane precursors
and are proteolytically cleaved by metalloproteinases to
yield the mature growth factor, which subsequently acti-
vates receptors on the same or on adjacent cells [6]. Fol-
lowing ligand binding, the EGFR dimerizes and becomes
tyrosine phosphorylated on distinct residues by the intrinsic
kinase activity of the receptor [7]. These residues represent
docking sites for first stage signal transducers with
enzymatic activity, such as phospholipase Cg, and adapterhttp://breast-cancer-research.com/content/2/3/184
proteins, such as Shc, Grb2 and Nck, which couple recep-
tor activation to downstream pathways, calcium metabo-
lism, and protein kinase C (PKC) signalling, transcription
and phospholipid turnover. Apart from these established
functions, the EGFR has been found to be a critical down-
stream element of signalling systems, including those
employed by G-protein-coupled receptors (GPCRs),
cytokine receptors, integrins and membrane-depolarizing or
stress-inducing agents [8–11].
The present review addresses aspects of cross-communi-
cation between cell-surface receptors and the EGFR, and
the implications of these cellular signalling network con-
nections for signal generation and diversification.
G-protein-coupled receptor-induced epidermal
growth factor receptor transactivation
Historical background
The classical functions of GPCRs are the generation of
second messengers such as cAMP, diacylglycerol and
inositol trisphosphate, and the modulation of ion channel
function [12]. In addition, GPCR agonists such as
lysophosphatidic acid (LPA), thrombin, endothelin-1, car-
bachol or bombesin regulate cellular growth, differentia-
tion and gene transcription through the Ras–mitogen-
activated protein kinase (MAPK) signalling pathway [13].
Because activating mutations in GPCRs or G-proteins
have been associated with cellular transformation [14,15],
human endocrine tumours [16] and thyroid adenomas
[17], understanding the mechanisms of G-protein-medi-
ated growth control is essential for targeted disease inter-
vention strategies. As an early point of convergence with
RTK-induced mitogenic signalling events, GPCRs stimu-
late the formation and membrane recruitment of protein
complexes that involve the adapter proteins Shc, Grb2
and the guanine nucleotide exchange factor Sos, which
results in the activation of the small GTPase Ras [18,19].
Because these processes are sensitive to the nonspecific
tyrosine kinase inhibitor genistein, the upstream activation
of kinases was proposed to be essential for G-protein-
mediated MAPK activation [20]. More recent studies have
identified the EGFR tyrosine kinase [21], as well as other
candidate mediators, including the cytoplasmic tyrosine
kinase Pyk2 [22] and members of the Src family [22,23]. It
is generally accepted that, depending on the expression
pattern, cell type and the activated receptor, these kinases
appear to contribute with varying extent to the activation of
the Ras–MAPK pathway by GPCRs. Less well understood
are the molecular mechanisms of how these tyrosine
kinases can be activated by heterotrimeric G proteins after
GPCR stimulation.
General characteristics of the transactivated epidermal
growth factor receptor
Since Daub et al [21] identified the EGFR to be essential
for endothelin-1, thrombin and LPA-induced MAPK activa-
tion and c-fos gene transcription in 1996, various studies
[24•,25,26] have demonstrated the critical role of this
inter-receptor cross-talk for mitogenic G-protein signalling
(Fig. 1). Common to all these reports is the observation
that GPCR-induced tyrosine phosphorylation of the EGFR
is very rapid, transient and comparable to stimulation with
low amounts of EGF [21,24•,25,26]. Furthermore, the
same signalling capacity of the transactivated and
EGF-activated EGFR [24•], carbachol-induced EGFR
dimerization [27] and the critical dependence on the intrin-
sic tyrosine kinase activity of the EGFR [21,24•,25–29]
points to an analogous mechanism of EGFR activation by
G-proteins or exogenous EGF. However, the speed of
transactivation and the absence of detectable amounts of
EGF-like ligands after G-protein activation [25,27] led to
the conclusion that GPCR-induced EGFR activation is
exclusively mediated by intracellular elements [8–11].
Involvement of Src kinases
Potential candidates as mediators of GPCR-induced
EGFR transactivation are members of the Src family of
cytoplasmic tyrosine kinases [30]. In COS-7 cells, Src
was reported to induce EGFR tyrosine phosphorylation
after stimulation of the Gi-coupled LPA and a2A-adrener-
gic receptors or overexpression of Gbg subunits, indepen-
dently of the intrinsic kinase activity of EGFR [31]. In the
same cell line, however, the Src kinase inhibitor PP1 only
Figure 1
EGFR transactivation by GPCRs and cytokine receptors. Various
signalling stimuli induce EGFR tyrosine phosphorylation to activate
different downstream signalling pathways. Apart from the activation of
the classical Ras–MAP kinase pathway, GPCR–EGFR cross-talk is
critical for G-protein-mediated stress fibre formation, ion channel
modulation or PI-3K-stimulated phospholipid turnover. In contrast to
cytokine-induced EGFR tyrosine phosphorylation by janus kinase
(Jak)2, GPCR-induced EGFR transactivation is dependent on the
intrinsic kinase activity of the receptor, and several cytoplasmic
mediators have been controversially discussed in the literature.Breast Cancer Research    Vol 2 No 3 Prenzel et al
slightly reduced LPA-induced EGFR transactivation [24•],
and recent data [32] suggest Src as a point of conver-
gence downstream of RTK transactivation and G-protein-
mediated focal adhesion complex assembly. A number of
reports have demonstrated a critical function of Src in
GPCR-induced Shc and Gab1 tyrosine phosphorylation
[24•], MAPK activation by GPCR agonists [24•,31,33]
and agonist-dependent a2-adrenergic receptor endocyto-
sis [34] as an early step in G-protein-mediated signal gen-
eration. Furthermore, the association of Src with Shc,
Grb2 and the EGFR after angiotensin II stimulation [25],
together with previously described Src-mediated phos-
phorylation of tyrosine residues Y845 and Y1101 of the
EGFR [35,36], suggest an additional means of receptor
activation utilized by GPCRs that is distinct from EGFR
autophosphorylation. Although the functional connection
between Src and the EGFR is still unclear, EGFR tyrosine
phosphorylation by Src was shown to be crucial for
EGF-induced and LPA-induced mitogenic responses [37].
This confirms previous studies [38] that implicated
EGFR–Src complex formation in malignant transformation
of breast cancer cell lines.
Calcium-dependent epidermal growth factor transactivation
Elevation of the intracellular calcium level and the activation
of the Ser/Thr PKC were both shown to be required for
Gq-coupled receptors to induce EGFR transactivation.
Although EGFR transactivation in response to carbachol or
uridine triphosphate stimulation of PC12 cells is sensitive
to PKC inhibition [27,39], bradykinin-stimulated EGFR tyro-
sine phosphorylation in COS-7 cells was shown to be
PKC-independent, but bradykinin treatment increased PKC
activity in parallel [40]. Nevertheless, in this case both path-
ways critically contribute to Gq-mediated MAPK activation.
Recently, calcium influx has been shown to be sufficient to
transactivate the EGFR and is necessary for various
GPCRs to increase the tyrosine phosphorylation of the
EGFR [25,28,41]. In PC12 cells [28,39], rat vascular
smooth muscle cells [25] or rat cardiac fibroblasts [42],
overexpression of the dominant-negative EGFR mutant
HER-CD533 or inhibition with the EGFR selective tyr-
phostin AG1478 strongly interfered with GPCR-induced
MAPK activation or mitogenic responses. Although in
PC12 cells the presence of extracellular calcium is neces-
sary for bradykinin-induced EGFR tyrosine phosphoryla-
tion, complexation of intracellular calcium upon treatment
with the chelating agent BAPTA-AM was sufficient to
inhibit angiotensin II-induced EGFR activation in cardiac
fibroblasts.
Because elevation in intracellular calcium or GPCR stimu-
lation can activate the PYK2 tyrosine kinase [39,43,44•],
its possible role as a link between GPCRs and the EGFR
was considered [39]. Nevertheless, in PC12 cells tetracy-
cline-inducible expression of a kinase-inactive PYK2
mutant did not effect EGFR transactivation by bradykinin
or membrane-depolarization [44•]. Interestingly, pharmaco-
logical inhibition of calcium/calmodulin-dependent protein
kinases completely abrogates EGFR tyrosine phosphory-
lation in response to membrane depolarization or
angiotensin II stimulation. This finding led to the identifica-
tion of these Ser/Thr kinases as possible mediators of
EGFR transactivation, at least in some cell types [42,44•].
Downstream of the transactivated epidermal growth factor
receptor
The signalling capacity of the transactivated EGFR is not
restricted to coupling GPCRs to the Ras–MAPK pathway,
but rather functions as a critical intermediate for Gq-, Gi-
and G12/13-coupled receptors to induce a multitude of bio-
logical responses. Several isoforms of phosphatidyl inosi-
tol-3 kinase (PI-3K) have been shown to be involved in
Gbg-dependent, LPA- or noradrenaline-induced MAPK
activation, but are likely to act downstream of or separate
from transactivated EGFR [24•,45–47]. Moreover, inhibi-
tion of EGFR function blocks LPA-induced PI-3K activity in
COS-7 cells [24•]. The complex formation of the docking
protein Gab1 with the EGFR and p85, the catalytic
subunit of PI-3K, was essential for LPA-stimulated PI-3K
lipid product generation [48•]. Furthermore, the p70 S6
kinase, a known effector of PI-3K that is critical for cell
cycle progression, is activated by endothelin-1 via
EGFR-dependent pathways [49].
Another cellular event regulated by various GPCRs that
depends on the EGFR function is the rearrangement of
the actin cytoskeleton and subsequent stress fibre forma-
tion via Ga13 but not Ga12 subunits [50,51•]. Finally, the
EGFR-dependent modulation of a potassium channel or
regulation of chloride secretion after carbachol stimulation
[26,27] represent additional responses within the complex
signalling network utilized by GPCRs, with the EGFR as
the major signal integrator.
Triple membrane-passing signal mechanism of epidermal
growth factor receptor transactivation
Generally, GPCR-induced EGFR transactivation has
been, so far, considered to be a ligand-independent
process, with several cytoplasmic players controversially
discussed as mediators of this inter-receptor cross-talk.
Experiments with different stable Rat-1 cell lines [52••]
have revealed the critical involvement of the EGFR ligand-
binding domain for EGFR transactivation, as well as the
possibility of intercellular transactivation between cocul-
tured cells in a cell-density dependent manner. This again
raised the question whether ligands for the EGFR can
contribute to GPCR-induced transactivation. Moreover,
LPA, carbachol and bombesin induce shedding of the pro-
HB-EGF growth factor precursor in COS-7 cells. Inhibi-
tion of this cleavage by the metalloproteinase inhibitorbatimastat completely abolished GPCR-induced EGFR
transactivation, as well as further downstream signalling
steps such as Shc and Gab1 tyrosine phosphorylation in
COS-7 and HEK293 cells [52••]. Because proteolytic pro-
cessing affects various transmembrane proteins, this criti-
cal role of metalloproteinases extends the repertoire of
known G-protein effectors and might open a new dimen-
sion of GPCR signalling. Furthermore, the ability of
HB-EGF to bind to cell-surface heparan sulphate proteo-
glycans prevents the immediate release of the ligand after
precursor cleavage, which might explain why mature
growth factors are not released into the culture medium
after GPCR stimulation. Additionally, transactivation and
the critical involvement of metalloproteinases for this
cross-communication were shown in prostate cancer
cells, which are known to regulate their growth via
autocrine pathways requiring either the bombesin or the
EGFR [52••]. This suggests a link between GPCR and
EGFR autocrine signals, which further emphasizes that
EGFR transactivation may contribute to pathophysiologi-
cal disease states. Although this triple membrane-passing
signal model provides new insights into mechanistic
details of transactivation (Fig. 2), it raises a variety of new
questions. The nature of the metalloproteinase(s) involved
and its regulation by heterotrimeric G-proteins will be the
key issue in the future.
Cross-talk between cytokine and epidermal
growth factor receptor family members
In addition to GPCRs, growth hormone and prolactin,
members of the cytokine superfamily, have been reported
to increase the EGFR tyrosine phosphorylation and
EGFR–Grb2 association in mouse liver in vivo [53••]. In
this case the EGFR was directly phosphorylated by the
Janus tyrosine kinase Jak2, which couples cytokine stimula-
tion to MAPK activation and c-fos gene transcription via the
transactivated EGFR. In contrast to GPCR-induced
effects, growth hormone only induces phosphorylation of
Tyr1068, the major Grb2 binding site of the EGFR, inde-
pendently of the intrinsic kinase activity of the receptor.
Furthermore, interleukin-6 was shown [54•] to stimulate the
autophosphorylation of HER2 in prostate cancer cells,
leading to increased HER2 and HER3 tyrosine phosphory-
lation, MAPK activation and cell proliferation. Clustering of
the interleukin-6 receptor b-subunit, gp130 and HER2 was
proposed to initiate these tyrosine phosphorylation events.
Cross-talk between integrins and epidermal
growth factor
Adhesion of cells to the extracellular matrix is mediated
through the integrin family of cell-surface receptors and
leads to the activation of multiple biological responses,
including calcium influx, increased protein tyrosine phos-
phorylation and activation of the MAPK cascade [55]. Inte-
grins, which are devoid of any intrinsic enzymatic activity,
have been demonstrated [56••] to transactivate the EGFR
in order to generate further cellular responses, most
notably adhesion-dependent cell survival. In accordance
with the first studies of the GPCR–EGFR cross-talk, those
investigators suggested, on the basis of medium-transfer
experiments, a ligand-independent mechanism. It would
be interesting to investigate the requirement of metallopro-
teinases in this process.
Cross-talk between platelet-derived growth
factor and epidermal growth factor receptor
Inter-receptor communication was not only demonstrated
between heterologous receptor classes, but also among dif-
ferent members of the RTK family. The EGFR and the
platelet-derived growth factor (PDGF)-b receptor are known
to interact physically [57], and EGF stimulation has been
shown to increase the tyrosine phosphorylation of PDGF-b
receptor and subsequent recruitment of PI-3K to the PDGF
receptor [58]. In contrast to tyrosine phosphorylation
events, signal regulation by serine or threonine phosphoryla-
tion has been poorly characterized, but is generally thought
to influence negatively the signalling capacity of RTKs such
as the EGFR and its relative HER2/neu [59]. Interestingly,
Bagowski et al [60] provided evidence that PDGF stimu-
lates threonine phosphorylation of T654 and T669 of the
EGFR, thus negatively regulating EGF-induced c-jun
amino-terminal kinase activation, and c-jun transcription and
cellular transformation. In this context the PKC-related
Ser/Thr kinase protein kinase D has been identified as a
potential mediator, but the detailed molecular mechanism of
this intracellular RTK–RTK cross-talk still remains elusive.
Conclusion
Signal transduction was often considered to be organized
in discrete signalling cassettes, linking receptor activation
http://breast-cancer-research.com/content/2/3/184
Figure 2
Triple membrane-passing signal mechanism of EGFR transactivation.
GPCR-induced EGFR transactivation involves as key elements
pro-HB-EGF, an EGF-like growth factor precursor, and a
metalloproteinase activity that is induced upon G-protein activation.
Therefore, this new mechanistic concept for ligand-dependent
GPCR–EGFR cross-talk entails three membrane-passing signals and
couples G-protein signalling to activation of the Ras–MAPK pathway.to cell division and gene transcription in a linear manner.
Recent studies have broadened this view to encompass a
complex network, which allows cross-communication
between separate signalling units with the EGFR as a key
element for signal integration and diversification from a
multitude of stimuli. We are just beginning to understand
the molecular mechanisms of RTK transactivation. On the
basis of identification of critical players, such as Tyr or
Ser/Thr kinases, metalloproteinases and growth factor
precursors, however, one must expect a general role of
this cross-talk in developmental and normal physiological
processes, as well as in pathophysiological disorders
such as cancer.
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